HOUSE BILL NO. 96

IN THE LEGISLATURE OF THE STATE OF ALASKA

THIRTY-THIRD LEGISLATURE - FIRST SESSION

BY REPRESENTATIVE PRAX

Introduced: 3/6/23

Referred: Health and Social Services, Labor and Commerce

A BILL

FOR AN ACT ENTITLED

- 1 "An Act relating to licensing and registration requirements for certain wholesale drug
- 2 distributors; and providing for an effective date."

3 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF ALASKA:

- *** Section 1.** AS 08.80.157(h) is amended to read:
- 5 (h) The board may suspend, revoke, deny, or refuse to renew the license of a facility or pharmacy on the following grounds:
- 7 (1) the finding by the board of violations of a federal, state, or local law relating to the practice of pharmacy, drug samples, wholesale or retail drug or device distribution, or distribution of controlled substances;
- 10 (2) a felony conviction under federal, state, or local law of an owner of 11 the facility or pharmacy or of an employee of the facility or pharmacy;
- 12 (3) the furnishing of false or fraudulent material in an application made 13 in connection with drug or device manufacturing or distribution;
- 14 (4) suspension or revocation by federal, state, or local government of a

1	license currently or previously held by the applicant for the manufacture or
2	distribution of drugs or devices, including controlled substances;
3	(5) obtaining remuneration by fraud, misrepresentation, or deception;
4	(6) dealing with drugs or devices that are known or should have been
5	known to be stolen drugs or devices;
6	(7) dispensing or distributing drugs or devices directly to patients by a
7	wholesale drug distributor other than a pharmacy unless
8	(A) the drug or device is a dialysate, drug, or device that is
9	(i) necessary to perform home dialysis;
10	(ii) approved by the United States Food and Drug
11	Administration, as required by federal law; and
12	(iii) delivered in its original, sealed, and labeled
13	packaging and only upon the receipt of a physician's order; and
14	(B) the wholesale drug distributor delivers the dialysate,
15	drug, or device directly to a patient with end-stage renal disease, or to the
16	patient's designee, for the patient's self-administration of dialysis therapy;
17	(8) violation of this chapter or a regulation adopted under this chapter.
18	* Sec. 2. This Act takes effect May 7, 2023.